Table 3.
Hematological toxicity
| Toxicity | Arm | n | Grade 0–2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
| Any hematological toxicity | Arm C | 34 | 2 (6%) | 3 (9%) | 29 (85%) |
| 32 (94%) | |||||
| Arm S | 33 | 0 (0%) | 10 (30%) | 23 (70%) | |
| 33 (100%) | |||||
| Leukopenia | Arm C | 34 | 5 (15%) | 16 (47%) | 13 (38%) |
| 29 (85%) | |||||
| Arm S | 33 | 3 (9%) | 23 (70%) | 7 (21%) | |
| 30 (91%) | |||||
| Neutropenia | Arm C | 34 | 2 (6%) | 3 (9%) | 29 (85%) |
| 32 (94%) | |||||
| Arm S | 33 | 1 (3%) | 9 (27%) | 23 (70%) | |
| 32 (97%) | |||||
| Thrombocytopenia | Arm C | 34 | 32 (94%) | 1 (3%) | 1 (3%) |
| 2 (6%) | |||||
| Arm S | 33 | 33 (100%) | 0 (0%) | 0 (0%) | |
| 0 (0%) | |||||
| Anemia | Arm C | 34 | 31 (91%) | 3 (9%) | – |
| Arm S | 33 | 31 (94%) | 2 (6%) | – |
Hematological toxicity was evaluated according to the JCOG Toxicity Criteria, an expanded version of the NCI‐CTC version 1.0. All hematological toxicities (possibly related to rituximab, or unknown relationship to rituximab) observed during the treatment and follow‐up period (for 6 months after the last cycle of CHOP for Arm C, and for 4 months after the last rituximab infusion for Arm S) are listed.